On March 30, 2026 SEED Therapeutics, Inc. ("SEED"), a clinical-stage biotechnology company specializing in molecular glue degraders, reported that it will have a poster presentation at the 2026 Annual Meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) ("AACR"), taking place on April 17 through 22, 2026 in San Diego, California.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details:
Title: RBM39 Degrader Anticancer Activity Against Neuroblastoma; MYC and CDKN2A/B as Potential Response Biomarkers
Presenter / Authors: James Finn, Imad Salhab, Haihong Jin, Fei Liu, Dong Liu, Yunkai Zhang, Xing Liu, James Tonra, Lan Huang, Dan Lu
Presentation Time: April 21, 2026, 2PM to 5PM PT
Location: Poster Section 15 at San Diego Convention Center
Session Category: Experimental and Molecular Therapeutics
Session Title: Proximity-Induced Drug Discovery 2
Poster Board Number: 12
Poster Number: 5785
(Press release, Seed Therapeutics, MAR 30, 2026, View Source [SID1234664045])